News & Events
Savara recently completed enrollment on a Phase IIa clinical study of AeroVanc's safety and efficacy, which was carried out at 40 cystic fibrosis centers throughout the U.S. Results are expected in Q1-2015.
MRSA in CF
MRSA infections have become increasingly common, with a prevalence of almost 30% of the U.S. cystic fibrosis patient population.